- Home
- MOLN
as 11-15-2024 4:00pm EST
Stocks
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
| Founded: | 2004 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 218.1M | IPO Year: | 2021 |
| Target Price: | $4.50 | AVG Volume (30 days): | 40.7K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.32 - $12.70 | Next Earning Date: | 08-26-2024 |
| Revenue: | $7,105,397 | Revenue Growth: | -31.03% |
| Revenue Growth (this year): | -17.87% | Revenue Growth (next year): | 29.41% |
Latest Molecular Partners AG News
MOLN Breaking Stock News: Dive into MOLN Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
GlobeNewswire
12 days ago
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
GlobeNewswire
17 days ago
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
GlobeNewswire
24 days ago
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
TipRanks
25 days ago
Molecular Partners Expands Radio-DARPin Collaboration
MT Newswires
a month ago
Molecular Partners, Orano Med Report Positive Preclinical Data on MP0712
GlobeNewswire
a month ago
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
GlobeNewswire
a month ago
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
Compare MOLN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MOLN Molecular Partners AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.